Hepatitis C Marketing: Applying Primary Care Tactics To Specialty Products

The Food and Drug Administration's back-to-back approvals of Hepatitis C therapies from Merck & Co. and Vertex Pharmaceuticals set the stage for a specialty-focused marketing battle the likes of which the biopharma industry hasn't seen in years.

The Food and Drug Administration's back-to-back approvals of Hepatitis C therapies from Merck & Co. Inc. and Vertex Pharmaceuticals Inc. set the stage for a specialty-focused marketing battle the likes of which the biopharma industry hasn't seen in years. For Merck, the launch of Victrelis (boceprevir) is an opportunity to showcase the value of its 2009 acquisition of Schering-Plough Corp., a deal that in recent months has lost luster as late-stage pipeline products have tanked and commercial uptake of medicines like Simponi (golimumab) have stalled. [See Deal] For Vertex, meanwhile, approval of Incivek (telaprevir) marks the biotech's official transition to a commercially focused organization, and catapults the firm into the ranks of the top biotechs, alongside Gilead Sciences Inc., Celgene Corp., and Biogen Idec Corp. ( See "Vertex: Preparing To Go Commercial," IN VIVO , September 2009 Also see "Vertex: Preparing to Go Commercial " - In Vivo, 1 September, 2009..)

That the launches of these two protease inhibitors are critical to how investors judge both companies is obvious. So is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.